Analysis of:
Epistem plc and AstraZeneca Complete Plucked Hair Biomarker Study for Oncology Drug Development (www.foxbusiness.com)
Analysis of RNA obtained from hair follicles can be used to guide drug development and therapy
Analysis of:
Diabetes Study Partially Halted After Deaths (www.nytimes.com)
".... a major federal study of more than 10,000 middle-aged and older people with Type 2 diabetes (DM) has found that lowering blood sugar actually increased their risk of death, researchers reported Wednesday."
Analysis of:
GlaxoSmithKline receives EMEA positive opinion for the approval of Hycamtin® (topotecan) hard capsules for the treatment of relapsed small cell lung cancer (www.pipelinereview.com)
GSK's oral topotecan was favorably reviewed in Europe for treatment of recurrent small cell cancer. IV topotecan is used in ovarian cancer , sarcomas, an rarely in hematological malignancies. The indication is quite narrow and oral use is complicated by lack of re-imbursement and poor patient...
Analysis of:
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer (jco.ascopubs.org)
In a phase II trial , Pfizer's Sutent produced an overall response arte of 11 % as second line treatment for patients with non-small cell lung cancer. The response rates is similar to approved agents for recurrent patients with an oral "targeted " drug and favorable safety profile. The role would be...
Analysis of:
FDA Grants Priority Review For Velcade(R) (bortezomib) for Injection In Patients with Newly Diagnosed Multiple Myeloma (www.pipelinereview.com)
Millennium Pharmaceuticals, Inc. (Nasdaq: MLNM) is pressing for approval of Velcade in a first line rather than second line + setting. This would definitely increase sales
Analysis of:
Takeda Doses First Patient in A U.S. Phase 1 Study of Hematide(TM) to Treat Chemotherapy Induced Anemia (www.pipelinereview.com)
Takeda is collaborating with Effamax to conduct a phase I trial investigating a new erythropoeitin stimulating agent ( ESA) in anemic patients with refractory solid tumors receiving chemotherapy. The study is well designed and if the new agent has efficacy of Aranesp ( Amgen) and Procrit ( J&...
Analysis of:
Multicenter, Phase II Trial of Sunitinib in Previously Treated, Advanced Non–Small-Cell Lung Cancer (jco.ascopubs.org)
Preliminarily appears to be effective in Non Small Cell Carcinoma of the Lung (NSCLCA). Overall response rates are comparable to standard second line agent efficacy, and its ORAL.
Analysis of:
Great Drug, but Does It Prolong Life? (www.nytimes.com)
For people without cardiovascular disease or > 70 there is no benefit to statins!!!!
Analysis of:
EntreMed Presents Interim Results for Phase 2 Carcinoid Tumor Study (www.pipelinereview.com)
Panzem is an oral formulation of 2-methoxyestradiol with multiple anti-tumor actions. These include tubulin disruption to halt mitosis (cell division), apoptosis stimulation and, similarly to Avastin (bevacizumab), angiogenesis inhibition.
87% of patients had stable disease...